Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma

In this HealthTree video, Dr. Adam Cohen discusses the Phase 2 STEM trial, which evaluates the safety and efficacy of cevostamab consolidation therapy following BCMA-directed CAR T-cell therapy in patients with heavily pretreated relapsed/refractory multiple myeloma.
Cevostamab, a bispecific antibody targeting FcRH5 and CD3, aims to enhance T-cell engagement against myeloma cells, potentially improving outcomes in this challenging patient population.

Presented at the 22nd International Myeloma Society Annual Meeting, the STEM trial's findings suggest that fixed-duration cevostamab consolidation is feasible and well-tolerated, with promising response rates.

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Видео Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma канала HealthTree Foundation for Multiple Myeloma